Abbott Laboratories (NYSE:ABT) Stock, Quote.Headers.trade-ideas

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Analyst Color

Biotech

Large Cap

News

Health Care

Initiation

Analyst Ratings

General

RBGLY

Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech growth and attractive valuation.

Abbott Laboratories&#39; Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst

Pre-Market Outlook

Markets

Trading Ideas

CHTR

This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Federal Reserve

Equities

Mid Cap

Broad U.S. Equity ETFs

Econ #s

ETFs

FTNT

NVDA

ORCL

SBUX

SCHW

Investors are anticipating the first cut to the federal funds rate in over four years at the September FOMC meeting. The market is divided on the magnitude of the cut, which could trigger significant reactions. Goldman Sachs data reveals the top S&amp;P 500 stocks to watch during Fed easing cycles.

20 S&amp;P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates

Arcblock

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), noting the company as a versatile large-cap with an attractive valuation.
Abbott has a diversified business model with solid distribution across segments (medtech, diagnostics, nutrition, pharmaceuticals) and geography. Medical devices are the company&#8217;s largest business, accounting for around 44% of total sales.
Abbott Laboratories&nbsp;reported second-quarter sales of $10.38 billion, up 4%, almost in line with the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.37 billion</a>.
Organic sales growth for the underlying base business was 9.3%, led by double-digit&nbsp;growth <a href="https://www.benzinga.com/24/07/39839507/abbott-laboratories-q2-earnings-revenue-and-profit-beat-estimates-nudges-up-annual-profit-guidance-o" target="_blank" rel="noreferrer noopener">in medical devices</a>.
Piper Sandler noted that the company struck a solid balance by achieving above-average growth for a large-cap medtech firm, maintaining strong efficiency metrics, and consistently paying dividends to shareholders.
Abbott has positioned itself as a high-single-digit growth company, placing it near the top of the large-cap medtech sector. Its medtech division has consistently contributed to overall growth, with expectations for double-digit expansion from 2024 to 2026.
Analyst Adam C. Maeder initiated coverage with an Overweight rating and a <a href="https://www.benzinga.com/quote/ABT/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $131</a>.
Talking about the valuation, the analyst highlighted that Abbott&#8217;s stock is currently valued at 22.3 times the consensus adjusted EPS estimates for 2025, reflecting a notable discount compared to its large-cap medtech peers.
This discount is partly driven by ongoing necrotizing enterocolitis (NEC) litigation, but the analyst contends that Abbott should still be trading at least on par with its peers, given its strong revenue growth and adjusted EPS outlook.
In July, Abbott stock fell following a U.S. jury&#8217;s ruling that found Abbott&#8217;s formula was responsible for a girl developing a severe bowel disease, leading to a hefty $495 million penalty. This verdict is part of nearly 1,000 lawsuits filed against Abbott Labs, its British rival&nbsp;Reckitt Benckiser Group PLC &#8211; ADR&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RBGLY#OTC">RBGLY</a>), both in U.S.<a href="https://www.benzinga.com/general/biotech/24/07/40006590/abbott-laboratories-tumble-nearly-8-in-pre-market-after-us-jury-charges-495m-penalty-for-disease-" target="_blank" rel="noreferrer noopener"> federal or state courts</a>.
&#8220;We don&#8217;t see much topline risk associated with the litigation, and we believe the Street is already pricing potential damages into the stock,&#8221; the analyst added.
ABT Price Action: Abbott Laboratories stock is down 1.07% at $113.66 at last publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40943923/theratechnologies-faces-potential-supply-disruption-for-its-top-selling-drug-warns-of-revenue-imp" target="_blank" rel="noreferrer noopener">Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays</a>.</li>
</ul>
Photo: Abbott

Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e60ff475f2b9b000113c537/adam-maeder">Piper Sandler analyst Adam Maeder</a> initiated coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with an Overweight rating and announced a price target of $131. Abbott shares fell 2.8% to close at $114.88 on Wednesday. <a href="https://www.benzinga.com/quote/ABT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Roth MKM analyst Scott Fortune initiated coverage on Turning Point Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Buy rating and announced a price target of $50. Turning Point Brands shares gained 0.9% to close at $39.03 on Wednesday. <a href="https://www.benzinga.com/quote/TPB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>R<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/641c1355c9c7840001d30a8f/james-rollyson">aymond James analyst James Rollyson</a> initiated coverage on Helix Energy Solutions Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) with a Strong Buy rating and announced a price target of $14. Helix Energy shares fell 1.8% to close at $9.84 on Wednesday. <a href="https://www.benzinga.com/quote/HLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital analyst Jonathan Atkin initiated coverage on Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Sector Perform rating and announced a price target of $345. Charter Communications shares gained 0.1% to close at $339.64 on Wednesday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst William Janela initiated coverage on Northern Oil and Gas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) with an Outperform rating and announced a price target of $47. Northern Oil &amp; Gas shares rose 0.3% to close at $36.17 on Wednesday. <a href="https://www.benzinga.com/quote/NOG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="512" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-1024x512.png" alt="" class="wp-image-556133" style="width:656px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-1024x512.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-768x384.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154.png 1325w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40925678/fedex-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-an">FedEx Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Piper Sandler analyst Adam Maeder initiates coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight rating and announces Price Target of $131.

Price Target

Piper Sandler Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $131

Investors are on edge in the lead-up to the Wednesday Federal Open Market Committee interest rate decision that is expected to deliver the first cut to the federal funds rate <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40921827/fed-decision-is-here-5-things-investors-need-to-know-ahead-of-wednesdays-pivotal-in">in over four years.</a>
The market is divided on the magnitude of the anticipated rate cut. Traders are assigning a 59% probability to a 50-basis-point cut, while a 41% chance is placed on a more modest 25-basis-point reduction. The size of the rate cut is crucial as it could trigger significant market reactions.
Should the Fed opt for a 50-basis-point cut, it may be perceived as an acknowledgment that interest rates are overly restrictive. This could lead to increased expectations for further rate cuts in the coming months, potentially fueling risk sentiment and driving stock prices higher.
Conversely, a 25-basis-point cut might disappoint investors who are betting on a more aggressive measure.
Since the start of 2022, the S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), has experienced an average move of plus or minus 1.3% during FOMC events, reflecting the market&#8217;s high sensitivity to Fed policy decisions.
Goldman Sachs equity analysts, including John Marshall, analyzed stock movements during the first rate cuts in the previous three Fed easing cycles (Sept. 18, 2007, July 31, 2019 and March 3, 2020).
The data highlights the average moves of several key S&amp;P 500 stocks with liquid options during these periods.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Rank</th>
<th>Name</th>
<th>Absolute Average Move</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Caesars Entertainment Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>)</td>
<td>5.9%</td>
</tr>
<tr>
<td>2</td>
<td>Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>5.5%</td>
</tr>
<tr>
<td>3</td>
<td>Capital One Financial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>)</td>
<td>4.6%</td>
</tr>
<tr>
<td>4</td>
<td>Charles Schwab Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>)</td>
<td>4.6%</td>
</tr>
<tr>
<td>5</td>
<td>Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>)</td>
<td>4.5%</td>
</tr>
<tr>
<td>6</td>
<td>Fortinet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>)</td>
<td>4.3%</td>
</tr>
<tr>
<td>7</td>
<td>Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>)</td>
<td>4.2%</td>
</tr>
<tr>
<td>8</td>
<td>American Express Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)</td>
<td>3.8%</td>
</tr>
<tr>
<td>9</td>
<td>Newmont Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>3.7%</td>
</tr>
<tr>
<td>10</td>
<td>Deere &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>)</td>
<td>3.6%</td>
</tr>
<tr>
<td>11</td>
<td>BlackRock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>)</td>
<td>3.6%</td>
</tr>
<tr>
<td>12</td>
<td>Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>)</td>
<td>3.5%</td>
</tr>
<tr>
<td>13</td>
<td>3M Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>)</td>
<td>3.3%</td>
</tr>
<tr>
<td>14</td>
<td>Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)</td>
<td>3.2%</td>
</tr>
<tr>
<td>15</td>
<td>JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)</td>
<td>3.2%</td>
</tr>
<tr>
<td>16</td>
<td>Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>)</td>
<td>3.0%</td>
</tr>
<tr>
<td>17</td>
<td>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>)</td>
<td>3.0%</td>
</tr>
<tr>
<td>18</td>
<td>Starbucks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)</td>
<td>2.9%</td>
</tr>
<tr>
<td>19</td>
<td>Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</td>
<td>2.7%</td>
</tr>
<tr>
<td>20</td>
<td>Verizon Communications Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</td>
<td>2.3%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40908202/10-etfs-investors-secretly-bought-before-the-feds-make-or-break-interest-rate-cal">10 ETFs Investors Secretly Bought Before The Fed&#8217;s Make-Or-Break Interest Rate Call</a></li>
</ul>
Federal Reserve illustration created using artificial intelligence via MidJourney.

20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates

Thursday, Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.
The <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/continuous-glucose-monitoring-cgm-sensor-recall-abbott-diabetes-care-inc-issues-recall-certain" rel="noreferrer noopener">use</a> of the affected product may cause serious adverse health consequences, including severe low blood sugar (hypoglycemia), which can cause central nervous system problems, loss of consciousness, seizures, coma, permanent brain damage, and death.
There have been two reported injuries. There have been no reports of death.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/08/40556465/dexcoms-stelo-device-brings-affordable-continuous-glucose-monitoring-to-type-2-diabetes-patients" rel="noreferrer noopener">Dexcom&#8217;s Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients</a>.
This&nbsp;<a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/what-medical-device-recall" rel="noreferrer noopener">recall</a> involves removing certain devices from where they are used or sold and does not apply to the FreeStyle Libre 3 reader or app.
The FreeStyle Libre 3 Continuous Glucose Monitoring System is intended to monitor glucose levels continuously. It helps people manage diabetes by detecting trends and tracking patterns in glucose levels so treatment can be adjusted as needed. It is indicated for single-patient use and requires a prescription.
In July, Abbott sent all affected customers an Urgent Medical Device Recall recommending discontinuing the use, disposing of any affected sensors, and requesting a replacement.
Concurrently, on Thursday, Abbott&nbsp;announced the U.S. availability of Lingo, the company&#8217;s first continuous glucose monitoring system, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40729936/abbotts-lingo-continuous-glucose-monitor-for-health-and-wellness-now-available-in-the-u-s" rel="noreferrer noopener">without a prescription</a>.
The Lingo system includes a biosensor and a mobile app designed for consumers who want to improve their overall health and wellness.
Lingo is based on Abbott&#8217;s FreeStyle Libre continuous glucose monitoring technology.
Abbott&#8217;s consumer biowearable, Lingo, is available for consumers 18 years and older not on insulin. Lingo tracks glucose in real-time and provides personal insights and coaching to help people build healthy habits, retrain their metabolism, and improve their overall well-being.
Price Action: ABT stock is down 0.82% at $113.46 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40736321/battle-over-compounded-weight-loss-medications-sustainability-and-regulation" target="_blank" rel="noreferrer noopener">Battle Over Compounded Weight-Loss Medications &#8211; Sustainability and Regulation</a>.</li>
</ul>
Photo via Shutterstock

Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock&#39;s price, but are they really important?
Let&#39;s take a look at what these Wall Street heavyweights have to say about Abbott (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
Abbott currently has an average brokerage recommendation of 1.57, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 21 brokerage firms. An ABR of 1.57 approximates between Strong Buy and Buy.
Of the 21 recommendations that derive the current ABR, 14 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.7% and 9.5% of all recommendations.
<h2>Brokerage Recommendation Trends for ABT</h2>
<img alt="Broker Rating Breakdown Chart for ABT" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ABT_09052024.png" style="width:100%" title="" /> 
The ABR suggests buying Abbott, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every &quot;Strong Sell&quot; recommendation, brokerage firms assign five &quot;Strong Buy&quot; recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock&#39;s future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock&#39;s price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
<h2>Zacks Rank Should Not Be Confused With ABR</h2>
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers&#39; vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company&#39;s changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
<h2>Is ABT a Good Investment?</h2>
In terms of earnings estimate revisions for Abbott, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $4.66.
Analysts&#39; steady views regarding the company&#39;s earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Abbott.
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Abbott.
<a href="https://www.zacks.com/stock/news/2332013/is-it-worth-investing-in-abbott-abt-based-on-wall-street-s-bullish-views?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2332013">To read this article on Zacks.com click here.</a>

Earnings

Is It Worth Investing in Abbott Based on Wall Street's Bullish Views?

<ul>
<li>Designed for people interested in improving their overall health and wellness</li>
<li>Provides real-time glucose data and personal coaching insights based on the body's reaction to nutrition, exercise and life's daily stressors</li>
<li>Available without a prescription;</li>
</ul>

Abbott's Lingo Continuous Glucose Monitor Now Available In U.S.

<ul>
<li>The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this debilitating condition
<ul>
<li>Approximately 2.8 million Americans each year are diagnosed with TRD, a form of major depressive disorder that has not responded to two or more treatments1&nbsp;</li>
</ul>
</li>
</ul>

Abbott Initiates Clinical Study Evaluating Use Deep Brain Stimulation System To Manage Severe Depression

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has fallen 7.59% since its last report. The company recently reported that it has 12.68 million shares sold short, which is 0.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724945416_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.59%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Abbott Laboratories's Recent Short Interest

Labcorp Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) is reportedly collaborating with U.S. health regulators to determine whether it should scale up its mpox testing capabilities, following global concerns over a newly detected <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40554882/tonix-pharma-collaborates-with-worlds-largest-vaccine-manufacturer-for-mpox-vaccine" rel="noreferrer noopener">virus strain outside Africa</a>.
According to Marcia Eisenberg, the company's chief scientific officer, Labcorp currently processes around 500 mpox tests monthly but can ramp up to 25,000 if necessary, Reuters noted, citing an emailed statement.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40418733/mpox-vaccine-maker-bavarian-nordic-targets-broader-access-with-european-submission-for-imvanex-ad" rel="noreferrer noopener">Mpox Vaccine Maker Bavarian Nordic Targets Broader Access With European Submission For Imvanex Adolescent Use During WHO Emergency</a>.
The company recently received U.S. clearance for a home collection kit that doctors can order for patients aged 18 and older who are suspected of having mpox.
The clade Ib variant, previously found in the Democratic Republic of Congo and surrounding regions, has been detected in countries like Sweden and Thailand.
Labcorp, which produces a PCR test to detect mpox, is among several companies working on enhancing mpox testing infrastructure. Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) stated it is also monitoring global demand and exploring ways to leverage existing HIV testing infrastructure for mpox and other diseases in collaboration with African regulators.
Roche emphasized that its production capacities are designed to adapt to fluctuating global needs.
Other major diagnostics companies are also involved. Quest Diagnostics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) offers mpox testing services, while Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) has developed the Alinity m test kit, which is authorized for emergency use in the U.S. as part of the ongoing response to the mpox outbreak.
Reuters also noted that Germany would donate 100,000 mpox vaccine doses from its military reserves to support efforts in containing the outbreak in Africa, a government spokesperson announced on Monday.
The government also plans to provide the World Health Organization with flexible funding to fight the virus and will back African partners through the GAVI vaccination alliance.
Germany currently holds around 117,000 doses of the Bavarian Nordic A/S (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNRY#OTC">BVNRY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNKF#OTC">BVNKF</a>)&nbsp;Jynneos vaccine, initially acquired for <a target="_blank" href="https://www.benzinga.com/news/24/08/40384390/mpox-declared-a-global-public-health-emergency-by-who-amid-rapid-international-spread" rel="noreferrer noopener">military stockpiling in 2022</a>.
Price Action: LH stock is up 0.29% at $231.56 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40558289/major-investor-says-galapagos-is-undervalued-plans-to-push-on-companys-performance-and-strategic-" target="_blank" rel="noreferrer noopener">Major Investor Says Galapagos Is ‘Undervalued,' Plans To Push On Company's ‘Performance' And ‘Strategic Opportunities'</a></li>
</ul>
Photo by NIAID via <a href="https://www.flickr.com/photos/niaid/52508743460/">Flickr</a>

Media

BVNKF

BVNRY

Laboratory Corporation Of America Holdings

RHHBY

Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain

In March, the FDA approved DexCom Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) Stelo Glucose Biosensor System as the first over-the-counter (OTC) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37522301/fda-approval-for-dexcoms-stelo-opens-continuous-glucose-monitoring-to-masses-analys" target="_blank" rel="noreferrer noopener">continuous glucose monitor (CGM)</a>. 
The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) intended for people 18 and older who do not use insulin.
On Monday, DexCom announced Stelo is now available for purchase without a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40547929/stelo-by-dexcom-the-first-over-the-counter-glucose-biosensor-in-the-u-s-is-now-available" rel="noreferrer noopener">prescription&nbsp;at&nbsp;Stelo.com</a>.
Stelo is a small biosensor worn on the back of the upper arm.
It is specifically designed to provide the 125 million Americans&nbsp;with Type 2 diabetes who are not using insulin and those with&nbsp;prediabetes with personalized glucose insights sent directly to their smartphones.
These insights reveal how food, exercise, and sleep can affect glucose—all without painful fingersticks.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39861919/abbott-labs-makes-marketing-push-for-new-glucose-monitors-targets-health-conscious-consumers" rel="noreferrer noopener">Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers</a>.
Users can buy a one-month supply online for $99 (for a single pack of two sensors (total wear time up to 30 days) or sign up for an ongoing subscription at $89 a month.
In June, the FDA approved two new over-the-counter continuous glucose monitoring (CGM) systems from Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>): Lingo and Libre Rio. These systems are based on Abbott&#8217;s FreeStyle Libre technology, which is now used by about <a href="https://www.benzinga.com/pressreleases/24/06/n39248164/abbott-receives-u-s-fda-clearance-for-two-new-over-the-counter-continuous-glucose-monitoring-syste" target="_blank" rel="noreferrer noopener">6 million people globally</a>.
Reuters noted that Lingo has been available in Britain since January for $152-$190 (120-150 pounds) per month.
Jake Leach, chief operating officer at Dexcom, told CNBC in an <a href="https://www.cnbc.com/2024/08/26/dexcom-launches-stelo-its-first-over-the-counter-continuous-glucose-monitor.html" target="_blank" rel="noreferrer noopener">interview</a> that Dexcom is working with Amazon to fulfill Stelo deliveries.
Dexcom said patients also have the option to use their flexible spending accounts and health savings accounts to pay for Stelo, CNBC noted.
Stelo is a small, gray device worn on the upper arm, about the size of a quarter and half an inch thick, with a 15-day lifespan before needing replacement. It wirelessly transmits data to a smartphone app, where users specify whether they have Type 2 diabetes, prediabetes, or neither. This information sets a &#8220;Target Range&#8221; for maintaining optimal glucose levels.
Price Action: DXCM stock is up 0.48% at $74.43 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40553848/baker-hughes-says-us-oil-and-gas-rig-count-declines-for-second-week-report" target="_blank" rel="noreferrer noopener">Baker Hughes Says US Oil And Gas Rig Count Declines For Second Week: Report</a></li>
</ul>
Photo: Shutterstock

DXCM

Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients

CODX

U.S. CDC Says Free At Home, Covid 19 Test Delivery Programs Will Reopen In Late September

In the preceding three months, 5 analysts have released ratings for Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $127.2, a high estimate of $143.00, and a low estimate of $120.00. This current average has decreased by 0.04% from the previous average price target of $127.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1724349655_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Abbott Laboratories is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$143.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$121.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Abbott Laboratories. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Abbott Laboratories's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Abbott Laboratories's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>Unveiling the Story Behind Abbott Laboratories</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Abbott Laboratories: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Abbott Laboratories's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 4.0%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Abbott Laboratories's net margin excels beyond industry benchmarks, reaching 12.55%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Abbott Laboratories's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.33% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Abbott Laboratories's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.79%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Abbott Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Abbott Laboratories Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Citigroup analyst Joanna Wiensch maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $119 to $127.

Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $127

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/08/21/final-trades-abbott-labs-nu-holdings-and-the-iyj.html">Halftime Report Final Trades</a>,&#8221; Karen Firestone of Aureus Asset Management said Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) has a strong pipeline and the <a href="https://www.benzinga.com/general/biotech/24/07/40006590/abbott-laboratories-tumble-nearly-8-in-pre-market-after-us-jury-charges-495m-penalty-for-disease-">stock is starting to move.</a>
On July 18, Abbott reported second-quarter sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 billion. Organic sales growth for the underlying base business was 9.3%, led by double-digit growth in Medical Devices. Abbott's adjusted diluted earnings per share was $1.14, beating the analyst estimates of $1.10.
Shannon Saccocia of NB Private Wealth named iShares U.S. Industrials ETF (CBOE: IYJ) as her final trade.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here </a>
Joseph M. Terranova of Virtus Investment Partners picked Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>).
On Aug. 13, Nu Holdings reported financial results for the second quarter after the market close.
Nu Holdings reported second-quarter revenue of $2.8 billion. The Brazilian bank's top-line results were up 65% on a year-over-year basis. Nu reported second-quarter adjusted net income of $563 million, up from $263 million in the second quarter of 2023.
Nu Holdings said it added 5.2 million customers in the second quarter, bringing total customers up to 104.5 million as of June 30. Monthly average revenue per active customer came in at $11.20.
Price Action:
<ul>
<li>Abbott Laboratories shares gained 0.6% to close at $111.39 on Wednesday.</li>
<li>iShares U.S. Industrials ETF gained 0.7% during Wednesday's session.</li>
<li>Nu Holdings fell 0.4% to settle at $14.40 on Wednesday.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/markets/24/08/40496479/around-1-5m-bet-on-this-real-estate-stock-check-out-these-3-stocks-insiders-are-buying"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40496479/around-1-5m-bet-on-this-real-estate-stock-check-out-these-3-stocks-insiders-are-buying">Around $1.5M Bet On This Real Estate Stock? Check Out These 3 Stocks Insiders Are Buying</a></li>
</ul>

Long Ideas

iShares Trust Dow Jones US Industrial Sector Index Fund

Abbott Laboratories, Nu Holdings And More On CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Abbott Laboratories, Nu Holdings, iShares U.S. Industrials ETF

<a href="https://abbott.mediaroom.com/2024-08-21-Abbott-Advances-Heart-Failure-Management-with-Aspirin-Free-Regimen-for-Patients-Receiving-the-HeartMate-3-TM-Heart-Pump" title="https://abbott.mediaroom.com/2024-08-21-Abbott-Advances-Heart-Failure-Management-with-Aspirin-Free-Regimen-for-Patients-Receiving-the-HeartMate-3-TM-Heart-Pump">https://abbott.mediaroom.com/2024-08-21-Abbott-Advances-Heart-Failure-Management-with-Aspirin-Free-Regimen-for-Patients-Receiving-the-HeartMate-3-TM-Heart-Pump</a>

'Abbott Advances Heart Failure Management With Aspirin Free Regimen For Patients Receiving The HeartMate 3 Heart Pump' - Abbott

Medtronic plc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdt#NYSE">MDT</a>) is scheduled to report first-quarter fiscal 2025 results on Aug 20, before the opening bell.
In the last reported quarter, the company&#39;s adjusted earnings of $1.46 exceeded the Zacks Consensus Estimate by 0.69%. Medtronic beat estimates in each of the trailing four quarters, the average surprise being 4.48%.
The Zacks Consensus Estimate for fiscal first-quarter revenues is pegged at $7.90 billion, suggesting growth of 2.5% year over year. The consensus estimate for first-quarter earnings is pegged at $1.20 per share, indicating no change on a year-over-year basis.
<h3>Estimate Trend</h3>
Earnings estimates for Medtronic have remained unchanged at $1.20 per share for the fiscal first quarter over the past 60 days.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/32/74604.jpg?v=757625008" style="border-style:solid; border-width:1px; height:310px; width:600px" /> 
Image Source: Zacks Investment Research
Let&#39;s look at how things have shaped up for Medtronic before the announcement.
<h3>Mixed Trend Ahead of Q1 Earnings</h3>
Since the past several quarters, Medtronic&#39;s earnings growth has been held back by headwinds like cost escalation and currency impacts. Although inflation stabilized a bit during the fiscal fourth quarter, it is still higher than the historical trend. The continued rise in raw material and labor costs, as well as oil price volatility, has been denting the company&#39;s profit. Further, a rising interest rate leading to increasing borrowing costs is concerning. In the fourth quarter of fiscal 2024, gross margin contracted 56 basis points to 64.6% on a 2.1% rise in the cost of revenues. Further, selling, general and administrative expenses rose 5.7% year over year. Adjusted operating margin contracted 251 bps year over year to 24.5%.
Like its peers, the impact of the present geopolitical situation, including sanctions and other measures being imposed in response to the Russia-Ukraine conflict, may have impacted fiscal first-quarter profits.
Added to this, unfavorable currency movements have been a major dampener over the last few quarters, as in the case of other important MedTech players too. Medtronic expects its fiscal 2025 first-quarter revenues to reflect an unfavorable impact of $85 million to $135 million from currency translation.
Despite these challenges, Medtronic has consistently showcased the resilience of its underlying business fundamentals, delivering mid-single-digit organic revenue growth for several quarters in a row. While its recent product launches are driving growth across multiple businesses, a swift pace of several compelling product approvals promises consistent growth in the years to come.
Particularly, the company&#39;s AFib, Structural Heart, robotics, neuromodulation, hypertension and diabetes businesses are expected to have registered growth in the to-be-reported quarter, banking on several new product launches. Among the company&#39;s Established Market Leaders, the company might have witnessed growth through the Cranial &amp; Spinal Technologies segment on the increasing adoption of AiBLE, Medtronic&#39;s spine technology ecosystem. Further, Mazor Robotics, StealthStation navigation, O-arm Imaging and Midas Rex powered surgical instruments are expected to have witnessed growth.
In Cardiac Pacing Therapies, the Micra leadless pacemaker franchise is expected to have recorded strong growth driven by the adoption of its latest generation, Micra AV2 and VR2. In Defibrillation Solutions, the Aurora EV-ICD&#39;s adoption is expected to have remained strong in the fiscal first quarter. Within Surgical, the company is expected to have seen strong growth within Advanced Energy product lines.
The Zacks Consensus Estimate for MDT&#39;s overall Cardiovascular business revenues in the first quarter of fiscal 2025 indicates a 2.6% year-over-year improvement.
Among the company&#39;s Synergistic businesses, Medtronic is expected to report strong growth within Cardiac Surgery, ENT and Endoscopy segments. Pelvic Health, Coronary, Peripheral Vascular and Neuromodulation too are expected to have registered growth in the first quarter.
Among Medtronic&#39;s Highest Growth Markets businesses, the company is likely to have gained traction within the Cardiac Ablation Solutions arm, driven by the strong sales of Pulse Field ablation products, which are more than offsetting declines in the cryo product line.
Medtronic&#39;s Diabetes unit recorded strong growth in the United States in the fiscal fourth quarter, with the global adoption of the MiniMed 780G system driving performance. This trend is also likely to have continued in the fiscal first quarter.
The Zacks Consensus Estimate for MDT&#39;s Diabetes arm revenues indicates an improvement of 6.1% year over year in the first quarter of fiscal 2025.
<h3>What Does Our Model Say?</h3>
Our proven model does not conclusively predict an earnings beat for Medtronic this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. However, that&#39;s not the case here.
MDT has an Earnings ESP of 0.00% and carries a Zacks Rank of 4 (Sell) currently.
<h3>Bigger Picture</h3>
In recent years, the company has made some foundational changes to the organization, including streamlining the operating model, improving global operations, supply chain and quality, and bringing in expertise from outside the industry. It is actively allocating capital to fast-growth MedTech markets and fueling innovative technologies in areas like robotics, AI and closed-loop systems that ensure its growth over the next decade.
Medtronic&#39;s revenues have improved and become more durable from implementing a performance-driven culture and changing incentives underlying the new product approvals in major markets. With top priority placed on restoring the company&#39;s earnings power, these actions are expected to eventually result in better-leveraged earnings growth through margin stabilization and improvement.&nbsp;
Medtronic&#39;s highest growth opportunities, comprising 20% of its revenues, are in markets that are large and growing faster than the overall company. For example, in Cardiac Ablation, it has significantly invested in the Electrophysiology arm to expand its share in the attractive $8 billion-plus market.
Further, in Diabetes, Medtronic&#39;s MiniMed 780G system recently gained a CE Mark for use with the Simplera Sync sensor and received FDA approval in August 2024. Within Structural Heart, the new Evolut FX system favorably positions the company in the $6 billion-plus TAVR (transcatheter aortic valve replacement) market. In March 2024, the Evolut FX+ TAVR system gained the FDA&#39;s approval for the treatment of symptomatic severe aortic stenosis.
<h3>Shares Underperform Industry and S&amp;P</h3>
In the fiscal first quarter, Medtronic stock lost 0.1% in contrast to the industry&#39;s 1.1% growth and the S&amp;P 500&#39;s rise of 8.2%.
<h3>Q1 Price Comparison</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d1/74605.jpg?v=1263401542" style="border-style:solid; border-width:1px; height:310px; width:600px" /> 
Image Source: Zacks Investment Research
<h3>Cheap Valuation</h3>
If we look at the value components, MDT has a Value Score&nbsp;of B at present.
This is evident from the Price/Earnings ratio. MDT shares currently trade at 15.27X forward earnings, well off its five-year high of 30.08X and below the median of 17.51X. The stock is also trading significantly below the industry&#39;s 20.84X.
The company is also trading at a significant discount to other industry players like Boston Scientific Corporation, with its current P/E being 30.18, and Abbott (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>), whose current P/E is 22.39X. This suggests that investors may be paying a lower price relative to the company&#39;s expected earnings growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/59/74606.jpg?v=438939871" style="border-style:solid; border-width:1px; height:310px; width:600px" /> 
Image Source: Zacks Investment Research
<h3>To Conclude</h3>
While Medtronic holds immense potential for long-term growth, given its momentum, ongoing comprehensive transformation, breakthrough innovations and exposure to strong secular growth markets, the company battles significant headwinds from macroeconomic issues and rising expenses, which can significantly dent its bottom-line growth. For now, it might be prudent for investors to avoid buying the stock and monitor MDT&#39;s upcoming results for a better entry point.
<a href="https://www.zacks.com/stock/news/2323880/should-you-buy-sell-or-hold-medtronic-mdt-before-q1-earnings?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2323880">To read this article on Zacks.com click here.</a>

Earnings Beats

Tech

Should You Buy, Sell or Hold Medtronic Before Q1 Earnings?

Global

Abbott's AVEIR DR, World's First Dual Chamber Leadless Pacemaker System, Now Available In Canada

AEMD

CMRX

GOVX

MRNA

SIGA

TNXP

WHO Says Expert Committee Will Propose Adoption Of Mpox Vaccines Under Emergency Use Listing Around Mid Sept

Morocco reports first mpox case amid ongoing global outbreak

Abbott's Still Crushing It

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) on September 13 and set a price target o...

Wells Fargo Keeps Their Buy Rating on Abbott Laboratories (ABT)

Least shorted S&P 500 stocks in August

Moderna was most shorted S&P 500 healthcare stock in August for second consecutive month

Senseonics Eversense 365 glucose monitor cleared in the U.S.

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a pri...

Abbott Laboratories (ABT) Gets a Buy from Wells Fargo

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating due t...

Buy Rating on Abbott Laboratories: Undervalued with Strong Growth Prospects Despite NEC Litigation

Abbott a new overweight at Piper Sandler; at attractive entry point

Abbott Laboratories declares $0.55 dividend

ANET

APDN

GOOG

GOOGL

NDAQ

PHCCF

RHHBF

SENS

Movers & Shakers

GCTK

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Press Releases

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose Monitoring System with Medtronic's Insulin Delivery Devices

Quebec Expands Public Reimbursement of Abbott's FreeStyle Libre® 2 Flash Glucose Monitoring System to More Adults with Diabetes

Opinion

As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

Abbott's AVEIR™ DR - World's First Dual Chamber Leadless Pacemaker System - Now Available in Canada

Abbott Expands its Pure Bliss™ Line of Infant Formulas to Include European-Made and Organic Products; Offers the First and Only Organic Liquid Formula Available at U.S. Retail Stores

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Abbott's Lingo™ Continuous Glucose Monitor for Health and Wellness Now Available in the U.S.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Abbott Laboratories

Abbott Laboratories (ABT) Forecast

Abbott Laboratories (NYSE:ABT) Stock, Quote.Headers.trade-ideas